Incyte Corp. shares climbed 1.4% in pre-open trading following an announcement that the company has reached a settlement with the Centers for Medicare & Medicaid Services over the Medicaid rebate classification of Opzelura (ruxolitinib) cream.
Under the terms detailed by the company, CMS will not treat Opzelura as a line extension of Jakafi (ruxolitinib) for purposes of Medicaid rebate rules. That distinction carries material financial consequences for how rebates are calculated, and Incyte simultaneously withdrew a lawsuit that had challenged the applicable regulations.
As a result of the settlement, Incyte expects to record a one-time, non-cash accounting benefit of approximately $246 million in the second quarter that ends June 30, 2026. The company framed the move as the elimination of a material liability tied to the Medicaid classification dispute.
Adding to the positive momentum, BMO Capital reevaluated its stance on Incyte, upgrading the stock from Underperform to Market Perform and increasing its price target from $75 to $94. BMO had downgraded the shares in July 2024 amid concerns about the company’s strategy facing Jakafi’s expected loss of exclusivity in 2029. The firm cited recent progress under new management as the reason for its revised view, while noting that uncertainties remain over Incyte’s revenue path into the 2030s after Jakafi’s exclusivity ends.
The market environment further supported gains in the sector. The Nasdaq Composite advanced 1.9% and the S&P 500 rose 1.1% on the day, with investor sentiment helped by reported progress in Middle East diplomatic talks and a decline in oil prices, according to market commentary accompanying the session.
Combined, the removal of the Medicaid classification liability and the analyst upgrade helped lift Incyte shares during pre-market trading. The stock traded near its session high of $99.62 and remained well above its 52-week low of $66.74.
Summary
Incyte announced a CMS settlement that spares Opzelura from being treated as a Jakafi line extension for Medicaid rebate purposes, and said it will take a one-time, non-cash benefit of about $246 million in Q2 2026. BMO Capital upgraded the stock to Market Perform and raised its price target to $94. Broader market strength also supported the share move.
Key points
- CMS settlement prevents Opzelura from being classified as a Jakafi line extension for Medicaid rebate rules - this removes a material liability for Incyte.
- Incyte expects an approximately $246 million one-time, non-cash benefit to be recorded in the quarter ending June 30, 2026.
- BMO Capital upgraded its rating to Market Perform and raised its price target to $94 from $75, citing progress under new management despite lingering questions about post-Jakafi revenue into the 2030s.
Risks and uncertainties
- Uncertainty remains about Incyte’s revenue trajectory after Jakafi is expected to lose exclusivity in 2029, affecting long-term forecasts for the company and the pharmaceutical sector.
- The one-time, non-cash benefit is an accounting gain and does not directly translate into ongoing cash flows, which may limit its impact on longer-term performance.
- Market sentiment that supported the intraday move - including progress in diplomatic talks and lower oil prices - could shift, altering the short-term trading environment for equities generally.